A federal jury in Delaware find that 3 of 4 patents in a 2nd infringement case between Volcano Corp. and St. Jude Medical do not infringe on Volcano, which drops a 4th from the case. Legal News, News Well, Cardiovascular, Patent Infringementread more
McKesson agrees to pony up more than $2 billion for medical supplies provider PSS World Medical. McKesson (NYSE:MCK) agreed to pay $29 per share for PSS World Medical (NSDQ:PSSI) and its medical supplies business in a deal worth $2.1 billion. News Well, 2012, MassDevice Earnings Roundup, Medical Supplies, Mergers & Acquisitions, Q3read more
Volcano Announces Previous St. Jude Medical Products Infringe Volcano Patent and Jury Verdicts in Patent Trials with St. Jude MedicalOctober 25, 2012 3:59 pm | by Bio-Medicine.Org | News | Comments
SAN DIEGO, Oct. 25, 2012 /- Volcano Corporation (NASDAQ: VOLC ), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that St. Jude Medical agreed that previous versions of its PressureWire® products infringed Volcano's 6,976,965 patent (a...
Medical device manufacturers have traditionally relied on their extrusion supply partners for affordable medical tubing for a variety of application areas. However, more and more, these OEMs are seeking greater capabilities and more design solutions from these same supply parterners. This article looks at how medical extrusion is impacting device development today.
Shares of Orthofix drop nearly 4% today after the medical device company reported lower 3rd-quarter profits and cut its guidance for 2012. Shares of Orthofix (NSDQ:OFIX) stock shed some 4% of their value today after the medical device company said its 3rd-quarter profits fell and lowered its guidance for the rest of the year. Lewisville, Texas-based Orthofix reported profits of $7.6 million, or 39¢ per share, on sales of $114.8 million during the 3 months ended Sept. 30, for a 38.7% profit slide and a 2.1% decrease in sales. News Well, 2012, MassDevice Earnings Roundup, Orthopedics, Q3read more
Fluigent and Micronit Microfluidics have entered into a co-promotion agreement, enabling to promote each others products.October 25, 2012 3:43 pm | by I-Micronews | News | Comments
Micronit has set-up a Fluigent fluid handling system at its site, for chip characterization and for demonstration purposes. The Parties aim at leveraging on each other technical expertise and market experience, to offer products that can be easily integrated into any microfluidics experiments for R&D laboratories and industrial applications.
First FDA approved subcutaneous implantable defibrillator available for patients at risk for sudden cardiac arrestOctober 25, 2012 3:24 pm | by Bio-Medicine.Org | News | Comments
CHICAGO, Oct. 25, 2012 /PRNewswire-USNewswire/ -- Sudden cardiac arrest (SCA) is a condition in which the heart suddenly stops pumping blood. When this occurs, blood stops flowing to the brain and other major organs. Recent estimates show that approximately 850,000 people in the United States are at risk of SCA, and most of the people who have SCA, die from it. But, rapid treatment of SCA by usi...
While coatings can offer an array of benefits to medical device components, in certain cases, they can also come with adverse effects that impact the overall efficacy of the product. An innovative technique—microstructure engineering—enables a surface treatment to be accomplished during the component fabrication process, providing an alternative to coatings.
STEWARTVILLE, Minn., Oct. 25, 2012 /- Rochester Medical Corporation (NASDAQ: ROCM ) will announce quarterly results after financial markets close on Tuesday, November 13, 2012. The Company will then hold a quarterly conference call Tuesday, November 13, 2012 to discuss its earnings report. The call will begin at 3:30 p.m., central time (4:30 p.m., eastern time)....
W.L. Gore wants the U.S. Supreme Court to hear an appeal of its $186 million loss to C.R. Bard in a patent infringement spat over a vascular graft patent. W.L. Gore & Assoc. asked the U.S. Supreme Court to hear an appeal of its $186 million patent loss to C.R. Bard (NYSE:BCR) over vascular graft technology. Legal News, News Well, Patent Infringementread more
Orthopedics maker Zimmer's Q3 profits dropped on sliding sales and European currency impacts, leading the company to narrow its full-year outlook to the lower end of previous expectations. Zimmer Holdings (NYSE:ZMH) narrowed its full-year earnings outlook as sales and profits slid during the orthopedic device maker's 3rd quarter. Zimmer's U.S. sales stayed flat during the 3 months ended Sept. 30, 2012, as compared with the same period last year, but European revenues slid 3%, much of that due to the currency exchange impacts. News Well, 2012, MassDevice Earnings Roundup, Orthopedics, Q3read more
St. Jude Medical shares are down 4% today after clinical trial results show no significant benefit from its Amplatzer heart implant. St. Jude Medical (NYSE:STJ) shares lost 4% today after studies of its Amplatzer heart implant failed to significantly reduce cryptogenic stroke compared with standard treatment with drugs. News Well, Cardiac Implants, Transcatheter Cardiovascular Therapeutics symposium (TCT)read more
Medical device giant Boston Scientific asks the FCC for permission to continue using restricted radio frequencies as the company attempts to complete enrollment in its ongoing MultiSense CRT-D monitoring study. Boston Scientific (NYSE:BSX) needs some extra time to complete its MultiSense CRM monitoring study, the company told the Federal Communications Commission in requesting an extended waiver to access a restricted radiofrequency band. News Well, Clinical Trials, Cardiac Rhythm Management, Research & Developmentread more
Edwards Lifesciences' Sapien transcatheter aortic valve implantation system shows sustained and growing survival benefits out to 3 years among inoperable patients with severe aortic stenosis. Edwards Lifesciences' (NYSE:EW) Sapien transcatheter aortic valve implantation system, the only TAVI device on the U.S. market, demonstrated sustained and increasing survival benefits out to 3 years among inoperable heart failure patients, according to newly unveiled study results. News Well, Clinical Trials, Replacement Heart Valves, Research & Development, Transcatheter Cardiovascular Therapeutics symposium (TCT)read more
Texas Instruments Incorporated (TI), leading the industry with the most complete wireless connectivity portfolio for embedded applications, today announced that its Bluetooth® v4.0 technology-based CC2560 and CC2564...